Role of Statins in Peri-Operative Medicine

被引:5
作者
Bagry, H. S. [1 ]
Carli, F. [2 ]
机构
[1] St Boniface Gen Hosp, Dept Anesthesia & Perioperat Med, Winnipeg, MB R2H 2A6, Canada
[2] McGill Univ, Montreal Gen Hosp, Dept Anesthesia D10 144, Ctr Hlth, Montreal, PQ H3G 1A4, Canada
关键词
HMG CoA reductase inhibitors; pleiotropic effects; isoprenoids; atherogenesis; inflammation; perioperative metabolism; surgery; vulnerable plaque; PREOPERATIVE LIPID-CONTROL; ACUTE CORONARY SYNDROMES; MYOCARDIAL-INFARCTION; VASCULAR-SURGERY; CARDIAC OUTCOMES; RENAL-FAILURE; DOUBLE-BLIND; THERAPY; SIMVASTATIN; RISK;
D O I
10.2174/138945009789108783
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Statins are widely prescribed cholesterol lowering agents that exert their effects by inhibiting 3-hydroxy-3methylglutaryl co-enzyme A reductase. With their modulatory effects on the atherogenic lipid profile, the role of statin therapy is expanding amidst the growing obesity epidemic. The cholesterol lowering effects of statin therapy remain central in the long term management of coronary artery disease and cerebrovascular disease. While statin therapy is used commonly to target elevated LDL cholesterol, there is an emerging evidence supporting its role during acute coronary syndromes and stroke. Clinical research into plaque histology, vulnerable high risk plaques and plaque rupture has improved our insight into the pathophysiology of these acute vascular events. Non lipid lowering effects of statin, the so called pleitrophic effects, have become the focal point of investigation. This review discusses recent experimental and clinical evidence supporting the role of statin in perioperative medicine.
引用
收藏
页码:850 / 857
页数:8
相关论文
共 58 条
[1]   Preoperative statin use and outcomes following cardiac surgery [J].
Ali, IS ;
Buth, KJ .
INTERNATIONAL JOURNAL OF CARDIOLOGY, 2005, 103 (01) :12-18
[2]  
Amarenco P, 2006, NEW ENGL J MED, V355, P549
[3]   Acute renal failure following open heart surgery: risk factors and prognosis [J].
Bahar, I ;
Akgul, A ;
Ozatik, MA ;
Vural, KM ;
Demirbag, AE ;
Boran, M ;
Tasdemir, O .
PERFUSION-UK, 2005, 20 (06) :317-322
[4]   Metabolic syndrome and insulin resistance: Perioperative considerations [J].
Baty, Hema S. ;
Raghavendran, Sreekrishna ;
Carli, Franco .
ANESTHESIOLOGY, 2008, 108 (03) :506-523
[5]  
Campeau L, 1997, NEW ENGL J MED, V336, P153
[6]   Effects of atorvastatin on systemic inflammatory response after coronary bypass surgery [J].
Chello, M ;
Patti, G ;
Candura, D ;
Mastrobuoni, S ;
Di Sciascio, G ;
Agrò, F ;
Carassiti, M ;
Covino, E .
CRITICAL CARE MEDICINE, 2006, 34 (03) :660-667
[7]   Simvastatin increases neutrophil apoptosis and reduces inflammatory reaction after coronary surgery [J].
Chello, Massimo ;
Anselmi, Amedeo ;
Spadaccio, Cristiano ;
Patti, Giuseppe ;
Goffredo, Costanza ;
Di Sciascio, Germano ;
Covino, Elvio .
ANNALS OF THORACIC SURGERY, 2007, 83 (04) :1374-1380
[8]   Pravastatin inhibits arrhythmias induced by coronary artery ischemia in anesthetized rats [J].
Chen, Jianguang ;
Shen, Hua ;
Nagasawa, Yoshinobu ;
Mitsui, Kazuhiro ;
Tsurugi, Kunio ;
Hashimoto, Keitaro .
JOURNAL OF PHARMACOLOGICAL SCIENCES, 2007, 103 (03) :317-322
[9]   Preoperative lipid control with simvastatin protects coronary artery bypass grafts from obstructive graft disease [J].
Christenson, JT .
AMERICAN JOURNAL OF CARDIOLOGY, 2001, 88 (08) :896-+
[10]   Preoperative lipid-control with simvastatin reduces the risk of postoperative thrombocytosis and thrombotic complications following CABG [J].
Christenson, JT .
EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 1999, 15 (04) :394-399